Daridorexant Hydrochloride Tablets Market Opportunities, Growth Trends and Demand Analysis Report 2026-2032
On Dec 23, the latest report "Global Daridorexant Hydrochloride Tablets Market 2026 by Manufacturers, Regions, Types and Applications, Forecast to 2032" from Global Info Research provides a detailed and comprehensive analysis of the global Daridorexant Hydrochloride Tablets market. The report provides both quantitative and qualitative analysis by manufacturers, regions and countries, types and applications. As the market is constantly changing, this report explores market competition, supply and demand trends, and key factors that are causing many market demand changes. The report also provides company profiles and product examples of some of the competitors, as well as market share estimates for some of the leading players in 2026.
Get Report Sample with Industry Insights https://www.globalinforesearch.com/reports/3336687/daridorexant-hydrochloride-tablets
According to our (Global Info Research) latest study, the global Daridorexant Hydrochloride Tablets market size was valued at US$ 71.19 million in 2024 and is forecast to a readjusted size of USD 828 million by 2031 with a CAGR of 29.1% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Daridorexant Hydrochloride Tablets, marketed under the brand name Quviviq, is an innovative medication for the treatment of insomnia. As a dual orexin receptor antagonist (DORA) targeting both OX1 and OX2 receptors, Daridorexant helps regulate the sleep–wake cycle to improve both sleep onset and maintenance. Unlike benzodiazepines or Z-drugs, it does not act on GABA receptors, thereby reducing the risks of tolerance and dependence associated with traditional hypnotics. Administered orally, Daridorexant has a relatively short elimination half-life of approximately 8 hours, with peak plasma concentrations reached 1–2 hours post-dose. Common adverse effects include headache, somnolence, and fatigue. The U.S. FDA approved Daridorexant (25 mg and 50 mg) in January 2022 for the treatment of adult insomnia, followed by its U.S. launch in May 2022. Subsequent approvals and launches occurred across Europe, Canada, Japan, and other regions, making it the first EMA-approved DORA shown to improve both nighttime sleep and daytime functioning. In 2024, global sales reached 3.94 million tablets, with an average price of USD 17.56 per tablet and a gross margin of 71.2%, underscoring its strong clinical value and commercial performance worldwide.
In the U.S. and Europe, Daridorexant has entered a phase of rapid commercial expansion, supported by favorable clinical differentiation and growing physician adoption. Within the European Union, it is the most recent DORA approved by the EMA for improving both nighttime sleep and daytime functioning—an indication that broadens its clinical appeal beyond sleep onset and maintenance alone. Compared with other DORAs, its pharmacokinetic profile and well-balanced efficacy-safety ratio contribute to higher treatment adherence and positive real-world outcomes.
From a commercial standpoint, Daridorexant’s global rollout reflects a strategic blend of licensing, distribution, and market access initiatives. Regional partnerships enable efficient regulatory navigation and localized market penetration, ensuring coverage across hospitals, retail pharmacies, and online prescription platforms. Reimbursement listings in select countries further enhance patient accessibility, reinforcing uptake momentum. The integration of pharmacovigilance and patient-reported outcomes into post-marketing surveillance also supports sustained physician confidence and long-term safety validation.
Market uptake has been strongest in North America, Western Europe, and Japan, where supportive healthcare infrastructure and awareness campaigns accelerate adoption. In emerging markets such as China, Daridorexant’s entry underscores the expanding recognition of DORA-based therapeutics as the next-generation standard for insomnia care. Continued emphasis on education, real-world data generation, and stable supply chains will be critical to maintaining its growth trajectory.
Overall, Daridorexant exemplifies the evolution of insomnia therapeutics toward mechanism-driven, safety-conscious innovation. Its combination of differentiated pharmacology, robust clinical data, and strategic commercialization positions it as a leading agent in the global sleep medicine landscape—poised to define the post-benzodiazepine era of pharmacological sleep management.
This report is a detailed and comprehensive analysis for global Daridorexant Hydrochloride Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approval.
Daridorexant Hydrochloride Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type: 25mg、 50 mg
Market segment by Application: Hospital and Clinic、 Retail Pharmacies、 Other
Major players covered: Idorsia、 Simcere Pharmaceutical、 Nxera Pharma
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Daridorexant Hydrochloride Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Daridorexant Hydrochloride Tablets, with price, sales quantity, revenue, and global market share of Daridorexant Hydrochloride Tablets from 2021 to 2026.
Chapter 3, the Daridorexant Hydrochloride Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Daridorexant Hydrochloride Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment Daridorexant Hydrochloride Tablets the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the Daridorexant Hydrochloride Tablets sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2025.and Daridorexant Hydrochloride Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Daridorexant Hydrochloride Tablets.
Chapter 14 and 15, to describe Daridorexant Hydrochloride Tablets sales channel, distributors, customers, research findings and conclusion.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Daridorexant Hydrochloride Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
Contact Us:
Global Info Research
Web: https://www.globalinforesearch.com
Email: report@globalinforesearch.com
Get Report Sample with Industry Insights https://www.globalinforesearch.com/reports/3336687/daridorexant-hydrochloride-tablets
According to our (Global Info Research) latest study, the global Daridorexant Hydrochloride Tablets market size was valued at US$ 71.19 million in 2024 and is forecast to a readjusted size of USD 828 million by 2031 with a CAGR of 29.1% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Daridorexant Hydrochloride Tablets, marketed under the brand name Quviviq, is an innovative medication for the treatment of insomnia. As a dual orexin receptor antagonist (DORA) targeting both OX1 and OX2 receptors, Daridorexant helps regulate the sleep–wake cycle to improve both sleep onset and maintenance. Unlike benzodiazepines or Z-drugs, it does not act on GABA receptors, thereby reducing the risks of tolerance and dependence associated with traditional hypnotics. Administered orally, Daridorexant has a relatively short elimination half-life of approximately 8 hours, with peak plasma concentrations reached 1–2 hours post-dose. Common adverse effects include headache, somnolence, and fatigue. The U.S. FDA approved Daridorexant (25 mg and 50 mg) in January 2022 for the treatment of adult insomnia, followed by its U.S. launch in May 2022. Subsequent approvals and launches occurred across Europe, Canada, Japan, and other regions, making it the first EMA-approved DORA shown to improve both nighttime sleep and daytime functioning. In 2024, global sales reached 3.94 million tablets, with an average price of USD 17.56 per tablet and a gross margin of 71.2%, underscoring its strong clinical value and commercial performance worldwide.
In the U.S. and Europe, Daridorexant has entered a phase of rapid commercial expansion, supported by favorable clinical differentiation and growing physician adoption. Within the European Union, it is the most recent DORA approved by the EMA for improving both nighttime sleep and daytime functioning—an indication that broadens its clinical appeal beyond sleep onset and maintenance alone. Compared with other DORAs, its pharmacokinetic profile and well-balanced efficacy-safety ratio contribute to higher treatment adherence and positive real-world outcomes.
From a commercial standpoint, Daridorexant’s global rollout reflects a strategic blend of licensing, distribution, and market access initiatives. Regional partnerships enable efficient regulatory navigation and localized market penetration, ensuring coverage across hospitals, retail pharmacies, and online prescription platforms. Reimbursement listings in select countries further enhance patient accessibility, reinforcing uptake momentum. The integration of pharmacovigilance and patient-reported outcomes into post-marketing surveillance also supports sustained physician confidence and long-term safety validation.
Market uptake has been strongest in North America, Western Europe, and Japan, where supportive healthcare infrastructure and awareness campaigns accelerate adoption. In emerging markets such as China, Daridorexant’s entry underscores the expanding recognition of DORA-based therapeutics as the next-generation standard for insomnia care. Continued emphasis on education, real-world data generation, and stable supply chains will be critical to maintaining its growth trajectory.
Overall, Daridorexant exemplifies the evolution of insomnia therapeutics toward mechanism-driven, safety-conscious innovation. Its combination of differentiated pharmacology, robust clinical data, and strategic commercialization positions it as a leading agent in the global sleep medicine landscape—poised to define the post-benzodiazepine era of pharmacological sleep management.
This report is a detailed and comprehensive analysis for global Daridorexant Hydrochloride Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approval.
Daridorexant Hydrochloride Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type: 25mg、 50 mg
Market segment by Application: Hospital and Clinic、 Retail Pharmacies、 Other
Major players covered: Idorsia、 Simcere Pharmaceutical、 Nxera Pharma
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Daridorexant Hydrochloride Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Daridorexant Hydrochloride Tablets, with price, sales quantity, revenue, and global market share of Daridorexant Hydrochloride Tablets from 2021 to 2026.
Chapter 3, the Daridorexant Hydrochloride Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Daridorexant Hydrochloride Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment Daridorexant Hydrochloride Tablets the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the Daridorexant Hydrochloride Tablets sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2025.and Daridorexant Hydrochloride Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Daridorexant Hydrochloride Tablets.
Chapter 14 and 15, to describe Daridorexant Hydrochloride Tablets sales channel, distributors, customers, research findings and conclusion.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Daridorexant Hydrochloride Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
Contact Us:
Global Info Research
Web: https://www.globalinforesearch.com
Email: report@globalinforesearch.com
